Nephrology Doctors in La Crosse, WI Accepting Medicare

7 Nephrology doctors found. Showing 1 - 7

Thu Lam Nguyen, DO Internal Medicine - Nephrology Medicare: Medicare Enrolled Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300

Kevin A Rossiter, M.D. Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1910 South Ave, La Crosse, WI 54601 Phone: 608-782-7300

Dr. Arvind Kumar Garg, M.D. Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 700 West Ave S, La Crosse, WI 54601 Phone: 608-785-0940

Dr. Bashar A Omari, MD Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 700 West Ave S, La Crosse, WI 54601 Phone: 608-785-0940

Balaji Srinivasan, MD Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300

Dr. Sumaiya Waseem Siddiqi, MD Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300

Dr. Kumari Usha, MD Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300

News Archive

Consumers seek functional foods and supplements to enhance wellness quotient

An expanding aging population and increased consumer awareness boosts growth for the U.S. bone and joint health ingredients market. Consumers increasingly seek supplements and functional foods that enhance their wellness quotient and have strong scientific backup.

GSK strongly disagrees with conclusions reached in NEJM article on Avandia

GlaxoSmithKline has issued the following response to an article in the New England Journal of Medicine (NEJM) on Avandia (rosiglitazone maleate), a widely used and highly effective treatment for type 2 diabetes.

IQWiG dossier assessment finds no added benefit of lixisenatide

Lixisenatide (trade name: Lyxumia) has been approved in Germany since February 2013 for the treatment of type 2 diabetes mellitus in combination with oral blood-glucose lowering drugs or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products, the German Institute for Quality and Efficiency in Health Care examined whether this new drug offers an added benefit over the current standard therapy.

Researchers receive $435K to study how environmental factors affect genes that cause autism

Over the last decade, autism research has been primarily focused on finding genes that may "cause" autism. However, little information exists on gene-environment interactions that may increase risk for autism.

Read more Medical News

› Verified 1 days ago